Evolus, Inc. (EOLS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -85.71%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.14, delivering a surprise of -100%.Over the last four quarters, the company has surpassed c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) (Exact name of registrant as specified in its charter) _________________________________________________________________ Delaware 46-1385614 (State or other jurisdiction of incorporation or organization) 520 Newport Center Drive Suite 1200 Newport Beach, California 92660 (Address of Pri ...

First Quarter 2024 Highlights and Recent Developments First Quarter 2024 Financial Results 1 Evolus Reports First Quarter 2024 Results and Provides Business Update NEWPORT BEACH, Calif., May 7, 2024 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. "Coming off a record year in 2023, we're proud to carry the momentum into 20 ...

Svitlana HulkoInvestment Overview Evolus (NASDAQ:EOLS) went public in February 2018, its initial public offering ("IPO") raising ~$60m in gross proceeds, at a price of $12 per share. The company describes itself as "global performance beauty company with a customer-centric approach to delivering breakthrough products", in its 2023 annual report/10K submission, and its first and only commercial product, Jeuveau, was approved in the US and most European territories (where it is marketed and sold as Nuceiv ...

Earnings are a measure of the money a company is making. That is the reason why companies’ earnings growth captivates almost everyone, from the top brass to research analysts.Still, earnings acceleration works even better when lifting the stock price. Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in their price.Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if the rate of a company’s quarter-ove ...

Shares of Evolus, Inc. (EOLS) have gained 5% over the past four weeks to close the last trading session at $14.09, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $23 indicates a potential upside of 63.2%.The mean estimate comprises six short-term price targets with a standard deviation of $3.85. While the lowest estimate of $16 indicates a 13.6% increase from the current price ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and offering expenses. In additio ...

Dr. Rui Avelar, MD Chief Medical Officer and H e a d of R&D DISCLOSURES SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals rela ...

Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Louise Chen - Cantor Fitzgerald Navann Ty - BNP Paribas Serge Belanger - Needham & Company Uy Ear - Mizuho Securities Douglas Tsao - H.C. Wainwright Operator G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________ FORM 10-K _____________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 _____________________________ EVOLUS, INC. (Exact name of registrant as speci ...